{
    "clinical_study": {
        "@rank": "119469", 
        "arm_group": {
            "arm_group_label": "LDK378", 
            "arm_group_type": "Experimental", 
            "description": "750 mg once daily"
        }, 
        "brief_summary": {
            "textblock": "A single-Arm, open-label, multi-center, phase I/II study in which the pharmacokinetics,\n      safety, tolerability and efficacy of LDK378 will be assessed in adult Chinese patients with\n      locally advanced or metastatic NSCLC harboring a confirmed ALK rearrangement. Patients must\n      have demonstrated progression during or after crizotinib treatment whether or not previously\n      treated with cytotoxic chemotherapy. Approximately 60 patients will be enrolled. For the\n      first 15 patients enrolled in this study, patients will have an additional 5-day PK run-in\n      period before treatment period. The pharmacokinetics profile of LDK378 in Chinese adult\n      patients with ALK-rearranged NSCLC will be evaluated."
        }, 
        "brief_title": "LDK378 in Adult Chinese Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Non-Small Cell Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a phase I/II, open-label, multi-center study in which the PK, safety, tolerability\n      and efficacy of LDK378 will be assessed in adult Chinese patients with locally advanced or\n      metastatic NSCLC harboring a confirmed ALK rearrangement, defined as 15% or more positive\n      tumor cells as assessed using the Vysis ALK Break Apart FISH Probe Kit (Abbott Molecular\n      Inc.) or positive as assessed by immunohistochemistry (IHC) test (Ventana Medical Systems,\n      Inc) using rabbit monoclonal primary antibody assay (D5F3).\n\n      Patients must have demonstrated progression during or after crizotinib treatment whether or\n      not previously treated with cytotoxic chemotherapy.\n\n      Approximately 60 patients with locally advanced or metastatic NSCLC which carry ALK\n      -rearrangement will be enrolled in the study. The first 15 patients to be enrolled in the\n      study will have PK sampling over 120-hour during the 5-day PK run-in period following a\n      single oral dose at 750 mg. After the PK run-in period, the treatment period will start in\n      which LDK378 will be given starting on Cycle 1 Day 1 in a continuous daily oral dosing in\n      28-day cycles. Separated from these 15 patients, the rest of the enrolled patients will\n      receive LDK378 treatment at 750 mg QD on Cycle 1 Day 1.\n\n      Tumor response will be evaluated every 8 weeks (i.e. every 2 cycles) starting from the first\n      day of treatment with LDK378 until the time of RECIST-defined PD by investigator assessment,\n      a new anti-cancer therapy, withdrawal of consent for further follow-up, loss to follow-up or\n      death."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  Histologically or cytologically confirmed diagnosis of NSCLC that carries an ALK\n             rearrangement defined as positive using the FDA approved Vysis ALK Break Apart FISH\n             Probe Kit (Abbott Molecular Inc.) test and scoring algorithm (including positivity\n             criteria) or positive as assessed by the CFDA approved immunohistochemistry (IHC)\n             test (Ventana Medical Systems, Inc)\n\n          -  Age 18 years or older at the time of informed consent.\n\n          -  Patients must have stage IIIB or IV NSCLC at the time of study entry and have had\n             progressive disease during or after crizotinib treatment whether or not previously\n             treated with cytotoxic chemotherapy. If treated with chemotherapy, maximum 2 lines\n             are allowed.\n\n        Exclusion Criteria:\n\n          -  Patients with known hypersensitivity to any of the excipients of LDK378\n\n          -  Patients with symptomatic central nervous system (CNS) metastases who are\n             neurologically unstable or have required increasing doses of steroids within the 2\n             weeks prior to study entry to manage CNS symptoms\n\n          -  History of carcinomatous meningitis\n\n          -  Presence or history of a malignant disease other than NSCLC that has been diagnosed\n             and/or required therapy within the past 3 years.\n\n          -  clinically significant, uncontrolled heart disease."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 17, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02040870", 
            "org_study_id": "CLDK378A2109"
        }, 
        "intervention": {
            "arm_group_label": "LDK378", 
            "description": "750 mg once daily", 
            "intervention_name": "LDK378", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Non-Small Cell lung Cancer, NSCLC, ALK, LDK378", 
        "lastchanged_date": "May 16, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "state": "Beijing", 
                        "zip": "100730"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chongqing", 
                        "country": "China", 
                        "state": "Chongqing", 
                        "zip": "400037"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Guangzhou", 
                        "country": "China", 
                        "state": "Guangdong", 
                        "zip": "510030"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Changchun", 
                        "country": "China", 
                        "state": "Jilin"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chengdu", 
                        "country": "China", 
                        "state": "Sichuan", 
                        "zip": "610041"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hangzhou", 
                        "country": "China", 
                        "state": "Zhejiang", 
                        "zip": "310003"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "zip": "100039"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "zip": "100036"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "zip": "100021"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chongqing", 
                        "country": "China", 
                        "zip": "400038"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Guang Zhou City", 
                        "country": "China", 
                        "zip": "510120"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Guangzhou", 
                        "country": "China", 
                        "zip": "510060"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China", 
                        "zip": "200032"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I/II, Multicenter, Open-label, Single-arm Study of LDK378, Administered Orally in Adult Chinese Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib Study Type: Interventional", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "+41613241111"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "LDK378 PK parameters, including but not limited to AUClast, AUC0-24h, Cmax, Tmax, terminal T1/2, effective T1/2,acc, Racc, CL/F and Vz/F, as appropriate", 
                "measure": "Pharmacokinetics of LDK378 after daily oral dose", 
                "safety_issue": "No", 
                "time_frame": "10 cycles (28 days each)"
            }, 
            {
                "description": "Adverse events, vital signs, ECGs and laboratory abnormalities", 
                "measure": "Safety and tolerability of LDK378 at 750 mg once daily dose in Chinese adult patients with ALK-rearranged locally advanced or metastatic NSCLC", 
                "safety_issue": "No", 
                "time_frame": "10 cycles (28 days each)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02040870"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "ORR per RECIST 1.1 calculated as the proportion of patients with a best overall response defined as complete response (CR) or partial response (PR).", 
                "measure": "Antitumor activity of LDK378, as measured by overall response rate (ORR) to LDK378 by investigator assessment", 
                "safety_issue": "No", 
                "time_frame": "10 cycles (28 days each)"
            }, 
            {
                "description": "DOR, calculated as the time from the date of the first documented CR or PR to the first documented progression or all cause death", 
                "measure": "Duration of response (DOR) by investigator assessment", 
                "safety_issue": "No", 
                "time_frame": "10 cycles (28 days each)"
            }, 
            {
                "description": "DCR, calculated as the proportion of patients with best overall response of CR, PR, or SD.", 
                "measure": "Disease control rate (DCR) by investigator assessment", 
                "safety_issue": "No", 
                "time_frame": "10 cycles (28 days each)"
            }, 
            {
                "description": "TTR, calculated as the time from first dose of LDK378 to first documented response (CR+PR).", 
                "measure": "Time to response (TTR) by investigator assessment", 
                "safety_issue": "No", 
                "time_frame": "10 cycles (28 days each)"
            }, 
            {
                "description": "OIRR calculated as the ORR (CR+PR) of lesions in the brain for patients who have measureable disease in the brain at baseline.", 
                "measure": "Overall intracranial response rate (OIRR) by investigator assessment", 
                "safety_issue": "No", 
                "time_frame": "10 cycles (28 days each)"
            }, 
            {
                "description": "PFS, defined as time from first dose of LDK378 to progression or death due to any cause.", 
                "measure": "Progression free survival (PFS) by investigator assessment", 
                "safety_issue": "No", 
                "time_frame": "10 cycles (28 days each)"
            }, 
            {
                "description": "OS, defined as time from first dose of LDK378 to death due to any cause.", 
                "measure": "Overall survival (OS) by investigator assessment", 
                "safety_issue": "No", 
                "time_frame": "10 cycles (28 days each)"
            }, 
            {
                "description": "ORR per RECIST 1.1 calculated as the proportion of patients with a best overall response defined as complete response (CR) or partial response (PR).", 
                "measure": "ORR as assessed by Blind Independent Review Committee (BIRC)", 
                "safety_issue": "No", 
                "time_frame": "10 cycles (28 days each)"
            }, 
            {
                "description": "OIRR calculated as the ORR (CR+PR) of lesions in the brain for patients who have measureable disease in the brain at baseline.", 
                "measure": "OIRR as assessed by Blind Independent Review Committee (BIRC)", 
                "safety_issue": "No", 
                "time_frame": "10 cycles (28 days each)"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}